Impact of Prior Treatment History on Recurrence After Complete Response to Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Given the high post-CR recurrence rate with atezo/bev in unresectable HCC, vigilant surveillance remains essential even after achieving CR, particularly in patients with ≥ 2 prior HCC treatments before atezo/bev initiation.
Authors
- Noboru Maeda
- Kaori Mukai
- Makiko Urabe
- Kenji Ikezawa
- Kunihito Gotoh
- Hidenari Hongyo
- Hiroshi Wada
- Ryoji Takada
- Tasuku Nakabori
- Yugo Kai
- Kazuyoshi Ohkawa
- Masaki Kawabata
Institutions
- Osaka International Cancer Institute (JP)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2026-01-26
- DOI
- https://doi.org/10.1002/cam4.71552
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00